Navigation Links
Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
Date:2/7/2013

rrants, net profit for Q3 FY13 would have been US$24.3 million or basic earnings per share ("basic EPS") of 1.41 US cents and diluted earnings per share ("diluted EPS") of 1.39 US cents. This compares to a net profit of US$26.8 million or basic EPS of 1.63 US cents and diluted EPS of 1.60 US cents, for Q3 FY12 after excluding the one-off non-operating gain of $279.6 million on re-measurement of the Group's interest in JWMS, goodwill impairment and the fair value adjustments for warrants.

Including exceptional items, net profit for Q3 FY13 was US$24.9 million, or basic EPS of 1.45 US cents and diluted EPS of 1.43 US cents, compared to a net profit of US$291.5 million, or basic EPS of 17.78 US cents and diluted EPS of 17.42 US cents, for Q3 FY12.

Performance Summary for FY13 Nine-month Period

Total product revenue in the FY13 nine-month period was US$202.1 million, a 38% year-on-year increase from US$146.0 million reported for the fiscal nine months ended 31 December 2011 ("FY12 nine-month period"). IVP revenue rose 42% to US$191.6 million, compared to US$134.9 million for the FY12 nine-month period, primarily driven by the Company's DES sales and the consolidation of JWMS' financial results starting from Q3 FY12. CCP revenue was US$10.5 million, a 6% decrease from the US$11.2 million for the FY12 nine-month period.

Overall total operating expenses accounted for 46% of total revenue in the nine months of FY13, compared to 45% for the FY12 nine-month period. S&M expense was US$66.2 million, G&A expense was US$29.2 million, while R&D expense was US$17.5 million.

For the FY13 nine-month period, the Group's operating profit was US$94.7 million, representing a 34% year-on-year increase from the same period last year.

Financial Guidance for FY13

Year-to-date, the Company has achieved healthy growth in its product sales, in line with the original target. However, due to changes in the dynamics of the Japanese marke
'/>"/>

SOURCE Biosensors International Group, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
2. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
3. Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
5. Plaintiff in Prolift Vaginal Mesh Case Testifies She Can No Longer Work, Have Sex, or Function Normally, Rottenstein Law Group Reports
6. Mesa Labs Reports 18% Increase in Third Quarter Revenues
7. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
8. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
11. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for ... proven, simple and effective palliative treatment of advanced prostate ... is the first and only six-month intramuscular (IM) GnRH ...
... the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It,s against this backdrop that new product planning ... , ... , ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Juvent Sports ... growing list of major sports figures who are finding joint pain relief after using ... former #1 men’s tennis player in the world said, “For the first time in ...
(Date:8/31/2015)... ... August 31, 2015 , ... According to book reviewer ... Charge of Your Life with Cancer is an excellent resource for everyone since ... Cancer Solution to be helpful in explaining what cancer is in a easy to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Intellitec Solutions announced ... by bringing on board their 8th new staff member in 2015. With the potential ... the firm. Intellitec Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in ... test marketing a doctor note service to be made available to all patients ... for each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... ... 31, 2015 , ... Avid collector Andrew Hawley from Vintage Rock Posters announces ... This hand colored artwork is one of the most coveted Doors concert posters. The ... the doors played the Shrine, the band was one of the biggest bands ...
Breaking Medicine News(10 mins):Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... activity, appears to be able to detect awareness in some ... new Canadian study finds. Functional MRI (fMRI) is also ... but the high cost and limited availability of these devices ...
... HealthDay Reporter , THURSDAY, Nov. 10 (HealthDay News) -- People ... restless legs syndrome, but many people with Parkinson,s do report ... new Norwegian study. People with restless legs ... legs. This typically occurs at night during rest, and the ...
... can lead to major health issues, including significant cognitive ... Departments of Neurology, Neurosurgery and Psychiatry at NYU Langone ... Nov. 10, 2011 issue of the New England ... sudden, unexpected death in epilepsy (SUDEP) and offers guidance ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... disease that many parents, even some doctors, mistake for ... diagnosed or treated in time, it can lead to ... genetic studies, scientists have been unable to pinpoint the ... an international team of scientists organized by Jane C. ...
... 2011)A new national initiative, IPAL-EM (Improving Palliative Care in ... palliative care when seriously ill patients are admitted to ... the role of the palliative care in emergency medicine, ... challenge of cultures and mindset. Supported by the ...
Cached Medicine News:Health News:Brain Study Suggests Some Vegetative Patients Are Aware 2Health News:Brain Study Suggests Some Vegetative Patients Are Aware 3Health News:Classic Restless Legs Syndrome Not Linked to Parkinson's 2Health News:NYU Langone expert calls for awareness, research of sudden death in patients with epilepsy 2Health News:Flexible rack systems sort molecules 2Health News:Kawasaki disease linked to wind currents 2Health News:Kawasaki disease linked to wind currents 3Health News:IPAL-EM launches to improve palliative care in emergency medicine 2
... 20 fume containment system work station ... swing-down front panel hinges from top ... opening. The sides and front ... is impervious to most chemicals. ...
... The STREP A OIA MAX test delivers ... Group A Strep with a simple, easy-to-use ... This combination of performance, speed, and ease-of-use ... while reducing overall costs for diagnosing and ...
... The FLU OIA A/B test combines performance equivalence ... of Influenza A or B with a simple, ... minutes. The test has all the same procedural ... test will enable you decrease costs for unnecessary ...
... The Acceava Mononucleosis test provides ... Mononucleosis with a simple procedure that ... Side-by-side evaluations with competitive products will ... These attributes enable you to deliver ...
Medicine Products: